Copyright
©The Author(s) 2016.
World J Clin Pediatr. May 8, 2016; 5(2): 212-222
Published online May 8, 2016. doi: 10.5409/wjcp.v5.i2.212
Published online May 8, 2016. doi: 10.5409/wjcp.v5.i2.212
Level of evidence | Type of study |
1a | Systematic review (with homogeneity) of RCTs |
1b | Individual RCT (with narrow confidence interval) |
1c | All or none (when patients died before the treatment became available, and now some survive) |
2a | Systematic review (with homogeneity) of cohort studies |
2b | Individual cohort study (including low quality RCT) |
2c | “Outcomes” research, ecological studies |
3a | SR (with homogeneity) of case-control studies |
3b | Individual case-control study |
4 | Case-series (and poor quality cohort and case-control studies) |
5 | Expert opinion without explicit critical appraisal, or based on physiology, bench research or “first principles” |
- Citation: Bhayat SI, Gowda HMS, Eisenhut M. Should dopamine be the first line inotrope in the treatment of neonatal hypotension? Review of the evidence. World J Clin Pediatr 2016; 5(2): 212-222
- URL: https://www.wjgnet.com/2219-2808/full/v5/i2/212.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v5.i2.212